B-cells and T-cell receptor (BCR, TCR) repertoire affects the tumor immune microenvironment (TIME) and clinical outcomes in patients treated with immunotherapy . BCR diversity was more associated with antibody responses but not with the overall B cell infiltration, nor with measures related to intratumoral CD8+T cell activity .